Stoke Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Stoke Therapeutics's estimated annual revenue is currently $19.1M per year.
- Stoke Therapeutics's estimated revenue per employee is $110,202
- Stoke Therapeutics's total funding is $235.1M.
- Stoke Therapeutics's current valuation is $720.4M. (January 2022)
Employee Data
- Stoke Therapeutics has 173 Employees.
- Stoke Therapeutics grew their employee count by 22% last year.
Stoke Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
2 | Co-Founder and SVP, Head Discovery Research | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | CFO | Reveal Email/Phone |
5 | Chief Business Officer | Reveal Email/Phone |
6 | Chief Business Officer | Reveal Email/Phone |
7 | Chief Human Resources Officer | Reveal Email/Phone |
8 | Chief Commercial Officer | Reveal Email/Phone |
9 | Chief Financial Officer | Reveal Email/Phone |
10 | VP, Controller | Reveal Email/Phone |
Stoke Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Stoke Therapeutics?
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
keywords:N/A$235.1M
Total Funding
173
Number of Employees
$19.1M
Revenue (est)
22%
Employee Growth %
$720.4M
Valuation
N/A
Accelerator
Stoke Therapeutics News
Bank of America reduced their target price on shares of Stoke Therapeutics from $43.00 to $40.00 and set a buy rating for the company in a...
TANGO (Targeted Augmentation of Nuclear Gene Output) is Stoke's proprietary research platform. Stoke's initial application for this technology...
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics today announced that it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. The financing round was led by RTW Investments with pa ...
Stoke Therapeutics, a Bedford, Mass.-based biotechnology company, completed a $90m Series B financing. The round was led by RTW Investments with participation from founding investor Apple Tree Partners and new investors RA Capital Management, Cormorant Asset Management, Perceptive Advisors, fun ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $41.9M | 173 | 6% | N/A |
#2 | $38.9M | 175 | 36% | N/A |
#3 | $35.2M | 178 | 23% | N/A |
#4 | $54.4M | 183 | 6% | N/A |
#5 | $65.7M | 186 | 4% | N/A |